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Leigh Syndrome: Subgroup Aanalysis according to 
Mitochondrial DNA Mutation
Purpose: Leigh syndrome (LS) is a rare, progressive neurodegenerative disorder with 
characteristic abnormalities in the central nervous system. Such patients present 
with heterogeneous clinical symptoms and genetic abnormalities; thus, prognosis 
is difficult to anticipate. The present study investigates whether distinct patient 
characteristics are associated with mitochondrial DNA (mtDNA) mutation in LS 
patients.
Methods: : We retrospectively analyzed data from patients diagnosed with LS at 
our hospital who were assessed using genomic sequencing of mtDNA. A subgroup 
analysis was performed to divide patients according to the mtDNA sequencing 
results. 
Results: Among the 85 patients enrolled, 18 had mtDNA mutations. Most patients 
had lactic acidosis and a lactate/pyruvate ratio above 20, indicating respiratory chain 
abnormalities. In the subgroup analysis, the mutation group had a significantly 
higher female-to-male ratio, alanine level, ocular involvement, and midbrain and 
medulla abnormalities on magnetic resonance imaging (MRI).
Conclusion: The subgroup analysis indicates that mtDNA sequencing is 
recommended for female patients, or those who exhibit ocular involvement, high 
alanine levels, or MRI findings with lesions in the midbrain and medulla. 
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Introduction
Leigh syndrome (LS) is a rare, genetically heterogeneous, and progressive 
neurodegenerative disorder1-3). LS involves the progression of focal and necroti-
zing lesions in the central nervous system, including the basal ganglia, cerebel-
lum, and brainstem4). Clinical presentations include psychomotor delay, weak-
ness, hypotonia, ataxia, dystonia, brainstem dysfunction, respiratory difficulty, 
swallowing dysfunction, and ophthalmological abnormalities such as nystagmus 
and optic atrophy5). The age at onset of LS is typically between 3 and 12 months. 
Most patients die within a few years of being diagnosed6).
Since the identification of the first pathogenic mutation in a patient with LS in 
1991, more than 75 disease-associated genes have been identified. Several stu-
dies have reported mitochondrial DNA (mtDNA) mutations in approximately 10–
20% of LS cases6-8). These mutations are usually associated with defects involving 
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mitochondrial oxidative phosphorylation9). Mutations in 13 of 37 
mtDNA-encoded genes that encode subunits of mitochondrial 
respiratory chain complexes have been associated with LS8).
LS is a rare and heterogeneous disease; therefore, it is difficult 
to obtain large amounts of data from patients. The objective of 
the present study is to compare differences in clinical features, 
laboratory findings, and imaging characteristics of LS in indivi-
duals with and without mtDNA mutations.
Materials and Methods
1. Participants
This study was a retrospective analysis of patients diagnosed 
with LS and followed up at Gangnam Severance Hospital from 
March 2006 to February 2016. Patients who fulfilled the follow-
ing criteria were included: (1) characteristic features of LS on 
neuroimaging, i.e., symmetrical hyperintense lesions in the basal 
ganglia and/or brainstem on T2-weighted magnetic resonance 
imaging (MRI); (2) abnormal energy metabolism indicated by a 
severe defect in oxidative phosphorylation or pyruvate 
dehydrogenase complex activity9), and (3) genetic analysis of 
whole mtDNA performed at a diagnostic workup. All procedures 
conducted were approved by the Institutional Review Board of 
Gangnam Severance Hospital in Seoul, Korea.(3-2017-0618). 
2. mtDNA analysis
DNA was extracted from peripheral blood leukocytes or 
primary cultured fibroblast cells, using the QIAcube System and 
QIAamp DNA Blood Mini Extraction Kit (Qiagen, CA) and was 
stored in 10 mM of Tris buffer solution at -20℃. mtDNA was 
amplified using long-range polymerase chain reaction (PCR). 
PCR conditions were as follows: 98℃ for 30 seconds, 30 cycles 
at 98℃ for 10 seconds, 72℃ for 8 minutes 15 seconds, and a final 
extension at 72℃ for 10 minutes. PCR products were run on a 1% 
agarose gel, and the expected 16.5-kb fragments were excised. 
DNA was purified using Agencourt AMPure XP (Beckman 
Coulter, IN). Quantification was performed using 4200 TapeSta-
tion (Agilent, UK). We fragmented the PCR product into 150–
200-bp segments with NEBNext dsDNA Fragmentase® (New 
England Biolabs, MA), according to the manufacturer’s protocol. 
The enzyme-fragmented PCR product was used as the input for 
the Accel-NGS® 2S PCR-Free DNA Library Kit following the 
manufacturer’s protocol. Final libraries were evaluated on the 
4200 TapeStation and quantitated using Qubit (Thermo Fisher 
Scientific, MA). Libraries were sequenced by synthesis on MiSeq 
for paired 150-bp read lengths using Illumina MiSeq V3 Kits 
(Illumina, CA). The sequenced reads were mapped to the 
human mitochondria reference (NC_012920) with the Burrows-
Wheeler Aligner (BWA), and variants were identified with the 
Genome Analysis ToolKit (GATK). Sequence variants were 
filtered in accordance with various quality parameters.
3. Subgroup definitions and data analysis
Patients were divided into either a mtDNA mutation-positive 
or mtDNA mutation-negative group. The two groups were 
statistically compared and analyzed on the basis of biochemical 
screening tests, neuroradiological findings, and pathologic 
findings. Patient data included sex, age of first symptoms, organ 
involvement, biochemical study (i.e., serum lactate, serum 
pyruvate, lactate-pyruvate ratio, creatine kinase (CK), plasma 
amino acids, and urine organic acid), brain MRI findings, 
respiratory chain enzyme activities, muscle histochemistry, and 
mtDNA sequencing findings. Patients with known nuclear DNA 
(nDNA) mutations were excluded6-8).
4. Statistical analysis
Statistical analysis was performed using SPSS version 22.0 
(SPSS Inc., Chicago, IL). Descriptive statistics included the mean, 
standard deviation (SD), median, and range. Continuous 
variables are presented as means and were compared between 
groups using two-sample t-tests. Categorical variables are 
presented as counts and percentages and were compared 
between groups using the chi-square test and Fisher’s exact test. 
P values less than 0.05 were considered statistically significant. 
Results
Among the 85 patients who underwent mitochondrial gene 
analysis, 67 (78.8%) had normal mtDNA and 18 (21.2%) had 
Table 1. The Position of mitochondrial DNA (mtDNA) Mutations in 
Patients with Leigh Syndrome (LS) (n=18)
mtDNA position Prevalence
T10191C 5 (5.9%)
T8993C 4 (4.7%)
G13513A 2 (2.4%)
T8993G 2 (2.4%)
T10158C 1 (1.2%)
G14459A 1 (1.2%)
C11777A 1 (1.2%)
T9185C 1 (1.2%)
T9176C 1 (1.2%)
Total 18/85 (21.2%)
mtDNA, mitochondrial DNA.
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mtDNA mutations. The most frequent mutation, T1019C, a 
mutation in the ND3 gene of the mitochondrial respiratory chain 
(MRC) complex I, was present in 5 patients (5.9%)10,11). The 
prevalence of the position of a mtDNA mutation is shown in 
Table 1.
Of the 85 patients with LS, 41 were male and 44 were female 
(Table 2). The average age of the first clinical presentation was 
1.56 (SD=2.08) years old. All 85 patients (100%) had central 
nervous system involvement, and other organs that were 
affected are shown in Table 2. Subgroup analysis was performed 
to compare the mtDNA mutation positive and negative groups. 
The proportion of females was significantly higher in the 
positive group than in the negative group (P=0.022). The age at 
onset of first symptoms was significantly greater in the positive 
group than in the negative group (P=0.028). The incidence of 
ocular involvement was also significantly higher in the mtDNA 
mutation positive group (P=0.009). In contrast, there was no 
significant difference between the two groups in the involve-
ment of other organs. 
The laboratory data of all patients are summarized in Table 3. 
Table 2. Comparison of Pediatric Clinical Variation in Leigh Syndrome (LS) between  mitochondrial DNA (mtDNA) Mutation Positive and Negative 
Groups (n=85)
Clinical feature Specification Total (n=85) mtDNA (+) (n=18) mtDNA (–) (n=67) P-value
Sex (female) 44 (40.7%) 15 (75.0%) 30 (44.8%) 0.022*
Age at onset of first symptom (years) 1.56±2.08 2.34±2.69 1.30±1.79 0.028*
Organ involvement CNS 85 (100%) 18 (100.0%) 67 (100.0%)
Muscular 43 (50.6%) 9 (50.0%) 34 (50.7%) 0.955
Respiratory 24 (28.2%) 6 (33.3%) 18 (26.9%) 0.555
GI tract 33 (38.8%) 5 (27.8%) 28(41.8%) 0.279
Ear 4 (4.7%) 0 (0%) 4 (6.0%) 0.379
Eye 8 (9.4%) 5 (27.8%) 3 (4.5%) 0.009*
Heart 6 (7.1%) 1 (5.6%) 5 (7.5%) 1.000
Hematology 1 (1.2%) 0 (0.0%) 1 (1.5%) 1.000
Nephrology 5 (5.9%) 2 (11.1%) 3 (4.5%) 0.285
*P values <0.05 were considered statistically significant.
Table 3. Comparison of Biochemical Laboratory Findings in Patients with Leigh Syndrome (LS) with or without mitochondrial DNA (mtDNA) 
Mutations (n=85)
Biochemical laboratory findings Total (n=85) mtDNA (+) (n=18) mtDNA (–) (n=67) P-value Reference value
Lactate At the time of diagnosis 2.91±1.71 2.85±1.40 2.93±1.79 0.877 0.5-2.2mmol/L
Last visit 2.43±1.27 2.61±1.01 2.39±1.33 0.523
Pyruvate At the time of diagnosis 0.17±0.10 0.13±0.07 0.18±0.11 0.072 0.034-0.102 mmol/L
Last visit 0.16±0.07 0.15±0.06 0.16±0.0.07 0.941
Lactate/ pyruvate ratio At the time of diagnosis 21.89±28.37 36.53±13.52 17.96±10.18 0.189
Last visit 18.17±18.87 18.02±6.62 18.21±21.02 0.970
CK At the time of diagnosis 148.94±133.16 122.67±107.87 156.00±139.04 0.349 44-245 IU/L
Last visit 162.25±161.78 106.35±61.49 176.72±176.95 0.112
Plasma amino acid (n=72) Alanine 432.93±189.03 517.19±220.99 408.86±173.65 0.042* 143-439 nmol/mL
Glycine 329.4±920.72 705.94±1,948.72 221.82±75.08 0.336 81-436 nmol/mL
Proline 181.39±90.56 178.69±84.77 182.16±92.87 0.894 52-298 nmol/mL
Threonine 125.72±86.72 151.75±168.77 118.29±41.08 0.443 189.8 nmol/mL
Urine organic acid (n=59) Abnormal findings 28(47.5%) 6/11 (54.5%) 22/48 (45.8%) 0.602
mtDNA, mitochondrial DNA; CK, creatine kinase.
*P values <0.05 were considered statistically significant.
Table 4. Comparison of Leigh Syndrome (LS) Magnetic Resonance 
Imaging (MRI) Findings between mitochondrial DNA (mtDNA) 
Mutation Positive and Negative Groups (n=85)
Involved lesion Total (n=85) mtDNA (+) (n=18) mtDNA (–) (n=67) P-value
Basal ganglia 80 (94.1%) 17 (94.4%) 63 (94.0%) 1.000
Thalamus 28 (32.9%) 8 (44.4%) 20 (29.9%) 0.242
Brainstem 31 (28.7%) 10 (55.6%) 21 (31.3%) 0.058
  Midbrain 30 (35.3%) 11 (61.1%) 19 (28.4%) 0.010
  Pons 14 (16.5%) 4 (22.2%) 10 (14.9%) 0.483
  Medulla 19 (22.4%) 8 (44.4%) 11 (16.4%) 0.022*
Cerebellum 23 (27.1%) 6 (33.3%) 17 (25.4%) 0.555
Atrophy 44 (51.8%) 7 (38.9%) 37 (55.2%) 0.218
Cortex 23 (27.1%) 6 (33.3%) 17 (25.4%) 0.555
White matter 35 (41.2%) 3 (16.7%) 32 (47.8%) 0.017*
mtDNA, mitochondrial DNA. 
*P values <0.05 were considered statistically significant.
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Biochemical laboratory measurements showed that the mean 
lactate and pyruvate levels were elevated, but in most patients, 
creatine kinase activity was not elevated relative to the reference 
value. In addition, no differences between the two groups were 
found for lactate, pyruvate, the lactate-pyruvate ratio, and CK 
levels and abnormal findings in urine organic acid. Plasma 
amino acid analysis revealed that the mean alanine level was 
elevated compared to the reference value and that the alanine 
levels of the two groups were significantly different (P=0.042).
The neuroimaging findings are summarized in Table 4. Of the 
85 patients, 80 (94.1%) had basal ganglia involvement, and 31 
(28.7%) had brainstem involvement, of which the midbrain was 
the most commonly affected site (30/31; 96.7%). In addition, 23 
of the 85 patients (27.1%) showed cortex involvement, and 35 
patients (41.2%) showed white matter involvement. MRI findings 
showed no significant differences in the involvement of the basal 
ganglia, thalamus, cortex, and cerebellum between the two 
groups. The ratio of abnormalities in the brainstem was 
significantly higher in the mtDNA mutation-positive group, 
especially in the midbrain (P=0.010) and medulla (P=0.014). The 
ratio of white matter involvement was lower in mtDNA mutation-
positive group (P=0.017).
A muscle biopsy biochemical enzyme assay identified 46 
patients (60.5%) with MRC 1 complex deficiency, 26 patients 
(34.2%) with MRC 4 deficiency, and 4 normal patients (5.3%). 
Moreover, 17 patients (21.5%) showed mitochondrial disease-
specific findings, such as ragged red fiber and abnormal 
histochemical staining. Three patients (3.8%) had nonspecific 
findings and 59 patients (74.7%) were normal. An electron 
microscope examination revealed 33 patients (41.8%) with 
pleioconia and 30 (38.0%) with megaconia. No differences were 
found between the two groups (Table 5).
Discussion
Previous studies have identified clinical differences according to 
the MRC complex type in LS12). More recently, however, studies have 
attempted to classify clinical features that are associated with 
genetic variation in patients with LS11-13). Phenotype analysis with the 
same mutation is limited because of the rarity of the disease. 
Therefore, our study performed a genome-wide analysis of mtDNA 
rather than analyze a single mutation. We analyzed age, sex, 
biochemical markers, and the pathology of the patients who 
underwent mtDNA analysis. We diagnosed and treated patients 
with LS for the past 10 years using the same analytical procedures 
at a single institution. 
LS typically presents clinical features in the first 2 years of life14). 
The mean age of clinical presentation in the patients in our study 
was 1.56 years, similar to the results of previous studies. Although 
previous studies of LS did not report sex differences6,15), we found 
that the proportion of females in the mtDNA mutation group was 
significantly higher than that in the non-mutation group (P=0.022). 
The age of onset was significantly higher in the mtDNA mutation 
positive group. We performed a genome-wide analysis of mtDNA 
for all the patients included in our study. Therefore, the patients 
without a mtDNA mutation likely have a nDNA mutation. LS with a 
nDNA mutation often presents with more severe outcomes than LS 
with a mtDNA mutation4). Therefore, due to nDNA mutations, the 
age of onset of the mtDNA mutation-free group may be younger. 
The clinical manifestation reported in our study is similar to that 
reported in previous studies, involving symptoms such as delayed 
development, seizure, motor weakness, loss of consciousness, 
muscle atrophy, and ataxia8). The incidence of ocular involvement in 
the mtDNA mutation-positive group was significantly higher; 
therefore, additional mitochondrial genetic testing should be 
considered.
Screening tests for LS include an analysis of lactate and pyruvate 
Table 5. Comparison of Diagnostic Evaluation in mitochondrial DNA (mtDNA) Mutation Positive and Negative Groups of Patients with Leigh 
Syndrome (LS) (n=85)
Evaluation Findings Total (n=85) mtDNA (+) (n=18) mtDNA (–) (n=67) P-value
Biochemical enzyme assay (n=76) Normal 4 (5.3%) 0 (0.0%) 4 (6.7%) 0.915
MRC complex I defect 46 (60.5%) 10 (62.5%) 36 (60.0%)
MRC complex IV defect 26 (34.2%) 6 (37.5%) 20 (33.3%)
Light microscope findings (n=79) Normal 59 (74.7%) 9 (56.3%) 50 (79.4%) 0.055
Specific 17 (21.5%) 5 (31.3%) 12 (19.0%)
Nonspecific 3 (3.8%) 2 (12.5%) 1 (1.6%)
Electron microscope findings (n=79) Normal 44 (55.7%) 10 (62.5%) 34 (54.0%) 0.540
Pleioconia 33 (41.8%) 6 (37.5%) 27 (42.9%) 0.698
Megaconia 30 (38.0%) 5 (31.3%) 25 (39.7%) 0.535
mtDNA, mitochondrial DNA; MRC, mitochondrial respiratory chain.
*P values <0.05 were considered statistically significant.
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levels, the lactate/pyruvate ratio, serum amino acid abnormalities, 
and urine organic acid16,17). Oxidative phosphorylation deficiency 
may lead to lactic acidosis. Pyruvate accumulates and is eventually 
metabolized into lactate by lactate dehydrogenase or transaminated 
into alanine by alanine aminotransferase, leading to an increase in 
these two substances in the blood, urine, and cerebrospinal fluid18). 
Therefore, assessment of alanine levels is useful in screening and 
diagnosing mitochondrial diseases16,19,20). In our study, the alanine 
level was significantly higher in the mtDNA mutation group, 
indicating that alanine levels may be helpful in differentiating 
patients with mtDNA mutations.
Bilateral, symmetrical hyperintensities in T2-weighted images are 
a characteristic finding in LS15). These lesions are commonly found 
in the basal ganglia, especially in the putamen, or in variable areas 
within the brainstem, such as the substantia nigra, nucleus ruber, or 
medulla oblongata12,21).  In our study, brain involvement was present 
in all patients, and most of the patients had lesions in the basal 
ganglia or brainstem. In particular, the ratio of midbrain and 
medulla lesions in the brainstem was significantly higher in the 
group with mtDNA mutations than those in the group without 
mtDNA mutations (P=0.010 and 0.022, respectively). In the mtDNA 
mutation-positive group, the proportion of white matter 
involvement, a nonspecific finding in LS, was significantly lower 
than that in the non-mutation group (P=0.017). Previous studies that 
analyzed MRI features and the MRC complex reported no specific 
correlations between MRI findings and MRC complex type22). In 
contrast, a previous investigation has reported a difference in MRI 
findings between groups with and without nDNA mutations, such 
as the SURF1 mutation23). Our study found a significant difference in 
MRI findings between mtDNA mutation-positive and -negative 
groups. Thus, MRI findings correlate better with genetic findings 
than with pathologic findings. Imaging differences can signal 
differences in the natural course of the disease, suggesting that 
clinical differences in treating individuals with LS may depend on 
the presence of mtDNA mutations.
Although LS is a single syndrome, over 75 genes are known to 
cause this disease9). These genes are important for oxidative 
phosphorylation7). The gold standard of LS diagnosis is gradually 
progressing from neuropathologic to genetic analysis because 
previous analyses have not uncovered clinically relevant correla-
tions24-26). Previous biochemical and clinical diagnostic methods for 
LS may require reanalysis and reclassification based on genotype. 
Diagnosis using genotype would improve predictions of the clinical 
course from the time of diagnosis. However, genome-wide mtDNA 
and nDNA analysis are difficult and costly. Thus, identifying the 
characteristics of the patients with LS that have mtDNA mutations 
could present relevant criteria for determining whether mtDNA or 
nDNA analysis should be performed. The results of our study 
suggest that mtDNA sequencing is recommended to evaluate 
patients with LS who are female or who exhibit ocular involvement, 
high alanine levels, or MRI findings of lesions in the midbrain and 
medulla.
A limitation of our study is that we could not compare the clinical 
features of the mtDNA mutation group and the nDNA mutation 
group. Further studies are required to analyze the characteristics of 
patients with mutations in nDNA.
요약
목적: Leigh 증후군은 진행하는 드문 신경퇴행성 질환으로 중추신
경계의 이상을 특징으로 한다. Leigh 증후군 환자들은 다양한 임상
증상 및 유전적 이상을 나타내기 때문에 예후를 예측하기 어렵다. 따
라서, 본 연구에서는 Leigh 증후군 환자들에서의 미토콘드리아 DNA 
돌연변이와 환자들의 임상 양상과의 연관성에 대해 분석하였다.
방법: Leigh 증후군으로 진단받은 환자 중에서 미토콘드리아 DNA
유전자 돌연변이 검사를 시행한 85명의 환자들의 자료를 후향적으로 
분석하였다. 미토콘드리아 DNA 돌연변이 결과에 따라 환자군을 나누
고, 집단 간의 임상 양상 차이를 통계 분석을 시행하였다.
결과: 연구에 참여한 85 명의 환자 중 18 명이 미토콘드리아 DNA 
돌연변이를 가지고 있었다. 대부분의 환자는 젖산수치 및 젖산/피루
베이트 비율이 20 이상이었으며 이는   호흡 연쇄 반응의 이상에 부합
하는 결과였다. 미토콘드리아 DNA 돌연변이가 있는 환자군은 미토콘
드리아 DNA 돌연변이가 없는 환자군과 비교하여, 여성 비율, 알라닌 
수치, 안구 침범, 자기 공명 영상(MRI)상 중뇌 및 숨뇌 이상이 통계학
적으로 유의하게 높았다.
결론: 임상적으로 Leigh 증후군이 의심될 때, 여성환자, 안구침범
을 보이는 환자, 높은 알라닌 수치를 보이는 환자, MRI상 중뇌나 숨뇌
에 이상소견이 보이는 환자에서는 미토콘드리아 DNA 돌연변이 검사
를 우선적으로 고려할 수 있다.
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